Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

Qiming leads Insilico’s $37M B round
Insilico Medicine Inc. (Hong Kong, China) raised $37 million in a series B round led by Qiming Venture Partners. Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners and other undisclosed investors including series A investors joined the round. The funding will be used to commercialize Insilico’s AI-based drug-discovery technology, build its senior management team and develop its pipeline in cancer, fibrosis, non-alcoholic steatohepatitis (NASH), immunology and CNS diseases for future partnerships.

10x Genomics bumps up IPO range
Single-cell analytics company 10x Genomics Inc. (Pleasanton, Calif.) raised the target price for its proposed 9 million share NASDAQ offering to $36-$38 from $31-$35. Priced at the midpoint of its range, the company would raise $333 million, $36 million more than it previously proposed, and be valued at $3.4 billion...